The analyses of the combinations of SerpinB2/NOS2, SerpinB2/CD206, and NOS2/CD206 groups, as well as the individual expressions of SerpinB2, NOS2, or CD206 alone did not demonstrate a significant difference in the DFS of patients with breast cancer (Supplementary Data 3). This evidence concerns the gene MRC1 and breast carcinoma.